Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MPM's Challenge: Investing the Largest Health Venture Fund

This article was originally published in Start Up

Executive Summary

MPM has raised a $900 million fund. What's it going to spend it on in these troubled times, when valuations across all sectors of the life sciences industry are slipping? MPM plans to direct two-thirds of the fund to product and technology companies, and a third to applied platform firms. The fund will aim for an 80/20 between pharmaceuticals and devices. MPM is particularly keen to find quality-of-life investments for its portfolio. In the pharma sector, MPM may at times take a stripped-down approach to building companies, but it will also do some buy-outs and generally be prepared to invest more and support start-ups longer than VCs did historically.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts